PARKVIEW HOSPITAL
- Type
- Teaching hospital
- Where
- Fort Wayne, IN
- Medicare CCN
- 150021
- Received
- $2,121,620 in 182 records, 2024 ($177,749 general, $1,943,871 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: PARKVIEW HOSPITAL INC Fuzzy (name and state)
- Federal award recipient: PARKVIEW HOSPITAL, INC. Fuzzy (name and state)
- Nonprofit: PARKVIEW HOSPITAL INC Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 100 | $177,749 |
| 2024 | Research payment | 82 | $1,943,871 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 82 | $1,943,871 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 69 | $139,559 |
| Space rental or facility fees (teaching hospital only) | 21 | $16,900 |
| Long term medical supply or device loan | 7 | $14,824 |
| Debt forgiveness | 2 | $6,215 |
| Grant | 1 | $250 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Merck Sharp & Dohme LLC | $277,521 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pemb | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $249,357 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $165,762 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfo | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $86,553 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $34,689 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pemb | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $25,596 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfo | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $23,513 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $18,960 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pemb | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $12,879 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2024 |
| 2024-12-31 | Stryker Corporation | $7,768 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $7,637 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $5,654 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Che | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $5,610 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $5,383 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers | 2024 |
| 2024-12-31 | Stryker Corporation | $5,026 | Long term medical supply or device loan | In-kind items and services | CORE Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $4,678 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Trial of Pembrolizumab MK-3475 in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Partici | 2024 |
| 2024-12-31 | Sterilmed, Inc. | $4,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Sterilmed, Inc. | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Merck Sharp & Dohme LLC | $864 | Research payment | In-kind items and services | Drug, ONCOLOGY | A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of | 2024 |
| 2024-12-31 | Stryker Corporation | $716 | Long term medical supply or device loan | In-kind items and services | SPY-PHI System Device, ENDOSCOPY | 2024 | |
| 2024-12-31 | Sterilmed, Inc. | $621 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | ABBVIE INC. | $192 | Research payment | In-kind items and services | M23-362 Ph2 Epcoritamab RR DLBCL and FL Outpatient Study | 2024 | |
| 2024-12-31 | Stryker Corporation | $8 | Long term medical supply or device loan | In-kind items and services | COMFORTGEL Device, PATIENT HANDLING - PH | 2024 | |
| 2024-12-30 | Linvatec Corporation | $79 | Long term medical supply or device loan | In-kind items and services | HELIX Device, GENERAL SURGERY | 2024 | |
| 2024-12-23 | ABBVIE INC. | $2,038 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 | |
| 2024-12-20 | Insulet Corporation | $2,775 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-12-18 | Tandem Diabetes Care, Inc. | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-12-16 | Merck Sharp & Dohme LLC | $123,433 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pemb | 2024 |
| 2024-12-12 | Medtronic, Inc. | $4,859 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-12-12 | Insulet Corporation | $3,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-12-11 | Roche Diagnostics Operations, Inc. | $191 | Research payment | Cash or cash equivalent | Elecsys Troponin T Gen 5 STAT Device, Cardiovascular | RD005477 | 2024 |
| 2024-12-05 | Insulet Corporation | $4,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-12-05 | ABBVIE INC. | $3,509 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 | |
| 2024-12-04 | Tandem Diabetes Care, Inc. | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-11-20 | Merck Sharp & Dohme LLC | $151,751 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2024 |
| 2024-11-20 | Merck Sharp & Dohme LLC | $93,593 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2024 |
| 2024-11-20 | Insulet Corporation | $5,175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-11-20 | Medtronic, Inc. | $1,870 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-11-20 | Tandem Diabetes Care, Inc. | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-11-13 | Insulet Corporation | $3,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-11-13 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-11-13 | Vapotherm Inc | $250 | Grant | Cash or cash equivalent | VAPOTHERM Device, RESPIRATORY | 2024 | |
| 2024-11-08 | Roche Diagnostics Operations, Inc. | $1,500 | Research payment | Cash or cash equivalent | Elecsys Troponin T Gen 5 STAT Device, Cardiovascular | RD005477 | 2024 |
| 2024-11-07 | ABBVIE INC. | $15,000 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoc | 2024 |
| 2024-11-07 | ABBVIE INC. | $3,509 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compar | 2024 | |
| 2024-11-06 | Insulet Corporation | $3,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-11-06 | Tandem Diabetes Care, Inc. | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-11-05 | ABBVIE INC. | $43,911 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compar | 2024 | |
| 2024-11-05 | ABBVIE INC. | $2,300 | Research payment | Cash or cash equivalent | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Part | 2024 | |
| 2024-11-05 | ABBVIE INC. | $1,400 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compar | 2024 | |
| 2024-11-04 | Merck Sharp & Dohme LLC | $192,277 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfo | 2024 |
| 2024-11-04 | Merck Sharp & Dohme LLC | $21,747 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without | 2024 |
| 2024-10-30 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-10-24 | Insulet Corporation | $375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-10-23 | Tandem Diabetes Care, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-10-18 | Medtronic, Inc. | $1,870 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-10-16 | Insulet Corporation | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-10-16 | UCB, Inc. | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-10-10 | Medtronic, Inc. | $5,053 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-10-10 | Insulet Corporation | $2,025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-10-09 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-10-03 | ABBVIE INC. | $4,897 | Research payment | Cash or cash equivalent | UBRELVY Drug, NEUROSCIENCE | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 |
| 2024-10-02 | Insulet Corporation | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-09-30 | Merck Sharp & Dohme LLC | $15,803 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Che | 2024 |
| 2024-09-30 | Merck Sharp & Dohme LLC | $1,964 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Mo | 2024 |
| 2024-09-26 | Insulet Corporation | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-09-23 | Medtronic, Inc. | $10,499 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-09-20 | Insulet Corporation | $6,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-09-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-09-19 | Merck Sharp & Dohme LLC | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VERQUVO Drug, CARDIOVASCULAR | 2024 | |
| 2024-09-19 | Karyopharm Therapeutics Inc. | $1,000 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/Placebo After Combination Chemotherapy for Patie | 2024 |
| 2024-09-18 | Roche Diagnostics Operations, Inc. | $5,000 | Research payment | Cash or cash equivalent | Elecsys Troponin T Gen 5 STAT Device, Cardiovascular | RD005477 | 2024 |
| 2024-09-18 | Tandem Diabetes Care, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-09-13 | Medtronic, Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-09-11 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-09-05 | PFIZER INC. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-09-05 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-09-04 | ABBVIE INC. | $11,290 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 | |
| 2024-09-03 | Insulet Corporation | $925 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-09-01 | ILLUMINOSS MEDICAL, INC. | $7,000 | Research payment | Cash or cash equivalent | Photodynamic Bone Stabilization Procedure Pack Device, Orthopedic | IlluminOss Device Global Registry | 2024 |
| 2024-08-28 | Abbott Laboratories | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ENDURITY Device, Cardiac Rhythm Management | 2024 | |
| 2024-08-27 | Medtronic, Inc. | $10,011 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-08-27 | Medtronic, Inc. | $2,750 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-08-22 | ABBVIE INC. | $7,334 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 | |
| 2024-08-22 | Insulet Corporation | $925 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-08-21 | ABBVIE INC. | $1,900 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 | |
| 2024-08-21 | Edwards Lifesciences Corporation | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-08-21 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-08-16 | Insulet Corporation | $2,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-08-14 | Tandem Diabetes Care, Inc. | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-08-13 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2024 | |
| 2024-08-07 | Insulet Corporation | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-08-07 | Tandem Diabetes Care, Inc. | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-08-02 | ABBVIE INC. | $14,835 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 | |
| 2024-08-01 | Insulet Corporation | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-07-26 | Insulet Corporation | $9,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-07-26 | SI-BONE, INC. | $4,000 | Research payment | Cash or cash equivalent | IFUSE IMPLANT SYSTEM Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2024 |
| 2024-07-24 | Sterilmed, Inc. | $316 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-07-23 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2024 | |
| 2024-07-22 | Olympus America Inc. | $3,448 | Debt forgiveness | In-kind items and services | EVIS EXERA III COLONOVIDEOSCOPE Device, Gastroenterology | 2024 | |
| 2024-07-10 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-07-05 | ABBVIE INC. | $4,692 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 | |
| 2024-07-02 | ABBVIE INC. | $3,700 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 | |
| 2024-07-01 | Karyopharm Therapeutics Inc. | $500 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/Placebo After Combination Chemotherapy for Patie | 2024 |
| 2024-07-01 | Karyopharm Therapeutics Inc. | $370 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/Placebo After Combination Chemotherapy for Patie | 2024 |
| 2024-06-27 | ABBVIE INC. | $3,300 | Research payment | Cash or cash equivalent | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Part | 2024 | |
| 2024-06-26 | Merck Sharp & Dohme LLC | $11,079 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2024 |
| 2024-06-25 | Insulet Corporation | $3,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-06-24 | Sterilmed, Inc. | $231 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-06-19 | Merck Sharp & Dohme LLC | $73,409 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2024 |
| 2024-06-18 | UCB, Inc. | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-06-17 | Medtronic, Inc. | $15,571 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-06-12 | Roche Diagnostics Operations, Inc. | $517 | Research payment | Cash or cash equivalent | Elecsys Troponin T Gen 5 STAT Device, Cardiovascular | RD005477 | 2024 |
| 2024-06-12 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-06-06 | ABBVIE INC. | $5,049 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 | |
| 2024-05-29 | AstraZeneca Pharmaceuticals LP | $6,795 | Research payment | Cash or cash equivalent | FARXIGA Drug, Cardiovascular and Metabolism | Dapagliflozin in Acute Decompensated Heart Failure | 2024 |
| 2024-05-28 | UCB, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-05-22 | Insulet Corporation | $6,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-05-20 | Merck Sharp & Dohme LLC | $13,026 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase II Trial of Pembrolizumab MK-3475 in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Partici | 2024 |
| 2024-05-19 | Medtronic, Inc. | $8,515 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-05-17 | Sterilmed, Inc. | $270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-05-16 | Insulet Corporation | $11,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-05-16 | Tandem Diabetes Care, Inc. | $1,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-05-06 | Merck Sharp & Dohme LLC | $8,750 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Che | 2024 |
| 2024-05-03 | SI-BONE, INC. | $3,331 | Research payment | Cash or cash equivalent | IFUSE IMPLANT SYSTEM Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2024 |
| 2024-05-02 | ABBVIE INC. | $3,500 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 | |
| 2024-04-30 | MOLNLYCKE HEALTH CARE US, LLC | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Alldress Device, Wound Care | 2024 | |
| 2024-04-25 | ABBVIE INC. | $10,251 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 | |
| 2024-04-25 | Insulet Corporation | $7,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-04-24 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-04-23 | Sterilmed, Inc. | $379 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-04-18 | Organon Llc | $700 | Long term medical supply or device loan | In-kind items and services | JADA SYSTEM Device, POSTPARTUM UTERINE HEMORRHAGING | 2024 | |
| 2024-04-12 | SI-BONE, INC. | $3,331 | Research payment | Cash or cash equivalent | IFUSE IMPLANT SYSTEM Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2024 |
| 2024-04-10 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-04-08 | AstraZeneca Pharmaceuticals LP | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ANDEXXA Biological, Rare Disease | 2024 | |
| 2024-04-05 | Medtronic, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-04-04 | ABBVIE INC. | $400 | Research payment | Cash or cash equivalent | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Part | 2024 | |
| 2024-04-03 | MicroVention, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-04-03 | Tandem Diabetes Care, Inc. | $900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-04-03 | AstraZeneca Pharmaceuticals LP | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ANDEXXA Biological, Rare Disease | 2024 | |
| 2024-04-03 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2024 | |
| 2024-04-02 | Insulet Corporation | $10,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-04-02 | ABBVIE INC. | $1,500 | Research payment | Cash or cash equivalent | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Part | 2024 | |
| 2024-03-27 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-03-26 | Medtronic, Inc. | $8,163 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-03-26 | Siemens Medical Solutions USA, Inc. | $2,766 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-03-25 | Sterilmed, Inc. | $282 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-03-20 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-03-13 | Medtronic, Inc. | $1,870 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-03-08 | Roche Diagnostics Operations, Inc. | $197 | Research payment | Cash or cash equivalent | Elecsys Troponin T Gen 5 STAT Device, Cardiovascular | RD005477 | 2024 |
| 2024-03-07 | ABBVIE INC. | $15,825 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with | 2024 | |
| 2024-03-06 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-03-05 | Insulet Corporation | $7,525 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-03-05 | Boston Scientific Corporation | $526 | Long term medical supply or device loan | In-kind items and services | Cryterion Device, Cryterion | 2024 | |
| 2024-02-29 | AstraZeneca Pharmaceuticals LP | $2,900 | Research payment | Cash or cash equivalent | SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastraz | 2024 | |
| 2024-02-28 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-02-22 | Insulet Corporation | $375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-02-22 | Sterilmed, Inc. | $362 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-02-21 | Tandem Diabetes Care, Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-02-20 | Medical Device Business Services, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NA Device, Trauma | 2024 | |
| 2024-02-13 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2024 | |
| 2024-02-10 | Organogenesis Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PURAPLY WOUND MATRIX Device, WOUND CARE | 2024 | |
| 2024-02-08 | Tandem Diabetes Care, Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-02-08 | Karyopharm Therapeutics Inc. | $370 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/Placebo After Combination Chemotherapy for Patie | 2024 |
| 2024-02-08 | Karyopharm Therapeutics Inc. | $370 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/Placebo After Combination Chemotherapy for Patie | 2024 |
| 2024-02-07 | ABBVIE INC. | $2,400 | Research payment | Cash or cash equivalent | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Part | 2024 | |
| 2024-02-05 | Insulet Corporation | $5,875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-02-05 | Draeger Medical Systems, Inc | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Babyroo TN300 Infant Radiant Warmer Device, Neonatal Care & Warming Therapy | 2024 | |
| 2024-01-31 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-01-29 | Medtronic, Inc. | $13,103 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-01-29 | Merck Sharp & Dohme LLC | $7,250 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Eto | 2024 |
| 2024-01-26 | Roche Diagnostics Operations, Inc. | $2,500 | Research payment | Cash or cash equivalent | Elecsys Troponin T Gen 5 STAT Device, Cardiovascular | RD005477 | 2024 |
| 2024-01-26 | Stryker Corporation | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | AXSOS Device, TRAUMA & EXTREMETIES | 2024 | |
| 2024-01-25 | AstraZeneca UK Limited | $14,004 | Research payment | Cash or cash equivalent | CALQUENCE Drug, Oncology | A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Le | 2024 |
| 2024-01-24 | Tandem Diabetes Care, Inc. | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-01-22 | Insulet Corporation | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-01-22 | Sterilmed, Inc. | $345 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-01-20 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2024 | |
| 2024-01-12 | Roche Diagnostics Operations, Inc. | $2,872 | Research payment | Cash or cash equivalent | Elecsys Troponin T Gen 5 STAT Device, Cardiovascular | RD005477 | 2024 |
| 2024-01-12 | SI-BONE, INC. | $1,500 | Research payment | Cash or cash equivalent | IFUSE IMPLANT SYSTEM Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2024 |
| 2024-01-10 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-01-03 | Tandem Diabetes Care, Inc. | $1,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Fort Wayne, IN, county Allen County, IN, state Indiana; placed by its city name.
| Measure | Place (city or town) Fort Wayne, IN | County Allen County, IN | State Indiana |
|---|---|---|---|
| Population B01003 | 268,589 | 392,378 | 6,851,073 |
| Population, 2020 census P1 | 263,886 | 385,410 | 6,785,528 |
| Median age B01002 | 35.0 | 36.2 | 38.1 |
| Under 18 B01001 | 24.3% | 25.4% | 23.3% |
| 65 and over B01001 | 15.2% | 15.6% | 16.8% |
| Households B11001 | 110,929 | 156,570 | 2,716,009 |
| Foreign born B05002 | 9.0% | 7.8% | 6.3% |
| Median household income B19013 | $61,422 | $70,737 | $71,957 |
| Median family income B19113 | $77,136 | $88,274 | $90,767 |
| Per capita income B19301 | $33,812 | $37,766 | $38,351 |
| Poverty rate B17001 | 16.0% | 12.5% | 12.3% |
| Unemployment rate B23025 | 5.6% | 4.7% | 4.3% |
| Civilian labor force B23025 | 138,501 | 201,715 | 3,472,016 |
| Mean commute (minutes) B08013 | 21.5 | 21.9 | 24.1 |
| Bachelor's degree or higher B15003 | 29.0% | 31.6% | 29.5% |
| Housing units B25001 | 118,657 | 166,285 | 2,976,568 |
| Owner-occupied B25003 | 61.9% | 68.9% | 70.6% |
| Renters B25003 | 38.1% | 31.1% | 29.4% |
| Median home value B25077 | $188,900 | $214,900 | $218,200 |
| Median gross rent B25064 | $999 | $1,021 | $1,062 |
| White, not Hispanic B03002 | 63.2% | 69.8% | 75.4% |
| Black B03002 | 14.0% | 10.5% | 9.1% |
| Hispanic or Latino B03002 | 10.6% | 9.0% | 8.6% |
| Asian B03002 | 6.1% | 5.3% | 2.6% |
| American Indian and Alaska Native B03002 | 0.1% | 0.0% | 0.1% |
Economy now FRED unemployment 3.4% in Sep 2026 (3.7% a year earlier); per capita personal income $66,455 in 2025, up 28% in five years (+3.2% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Fort Wayne, IN.
Comments